GlyTherix Ltd (GlyTherix), an Australian targeted radiotherapy company, and 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO) specializing in radiopharmaceuticals, are pleased to announce the execution of a Master Service Agreement. This collaboration combines 3DI’s cutting-edge radiopharmaceutical manufacturing expertise with GlyTherix’s innovative antibody therapies, advancing cancer treatments in the U.S. market.
Partnership at a Glance: Revolutionizing Cancer Treatment
- Manufacturing Agreement: 3DI will produce GlyTherix’s targeted radiotherapy antibody products, ^89^Zr-Miltuximab and ^177^Lu-Miltuximab, for upcoming U.S. clinical trials.
- Advanced Facilities: 3DI’s state-of-the-art cGMP facility in Little Rock, Arkansas, featuring dual-beam cyclotrons and specialized hot cells, will serve as the central manufacturing site.
- Radionuclide Production: 3DI will supply its cyclotron-produced GMP 89-Zirconium oxalate.
- Strategic Location: 3DI’s proximity to the Global FedEx hub ensures efficient distribution.
- Expanded Scope: The partnership supports potential future product distribution in the Asia-Pacific region.
Dr. Marc Berridge, President of 3D Imaging, commented, “3DI advances global healthcare by developing and producing quality radiopharmaceuticals. We’re excited to support GlyTherix in bringing their innovative Miltuximab products to U.S. clinical trials and distribution.”
Dr. Brad Walsh, CEO of GlyTherix, added, “We are very excited to continue strengthening GlyTherix’s development, supply and manufacturing efforts, distinguishing ourselves from the current generation of radiopharmaceuticals that have many logistical limitations due to very short half-lives. Through preclinical and clinical studies, GlyTherix is establishing itself as a leader in the advanced manufacturing of diagnostic and therapeutic nuclear medicines to improve treatment outcomes for adults with cancer.”
